FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W918310856> ?p ?o ?g. }

• W918310856 endingPage "152" @default.
• W918310856 startingPage "145" @default.
• W918310856 abstract "FTY720 is a promising drug in attenuating multiple sclerosis, prolonging survival of organ allograft, and many other protective effects. Its mechanism of action is considered to be mediated by the internalization of sphingosine 1-phosphate receptors (S1PRs). In the current study, we investigated the efficacy of FTY720 in Non-Obese Diabetic (NOD) mice, serving as a model of Dry Eye Disease (DED). NOD mice were divided into six study groups, i.e., FTY720-treated groups with 3 concentrations of FTY720 (0.05%, 0.005%, and 0.001%), 0.05% Cyclosporin A (CsA) treated group, normal saline treated group, and no treatment control group. FTY720 was reconstituted with normal saline and prepared as eye drop. The stability and production of tear film was measured by Tear Break up Time test (TBUT) and phenol red cotton thread test (PRCTT), respectively. Tear fluid washings were collected and assessed by ELISA. Cytokines were detected in lacrimal glands by RT-PCR. Inflammation in conjunctiva was assessed by immunohistochemistry, goblet cells and conjunctival epithelia were examined and evaluated by impression cytology. Our results indicated that FTY720 had a significantly therapeutic effect in NOD mice. After FTY720 intervention, TBUT and PRCTT data were greatly improved (p < 0.01), the interleukin 1β (IL-1β) level was markedly decreased in tear fluid washings compared to control and normal saline groups after 2 weeks (1.06 ± 0.12, Normal saline:0.97 ± 0.09 pg/ml, CsA:0.22 ± 0.02 pg/ml, 0.001% FTY720:0.23 ± 0.02 pg/ml, 0.005% FTY720:0.14 ± 0.03 pg/ml, 0.05% FTY720: 0.18 ± 0.03 pg/ml. CsA group and 3 FTY720 groups VS. control group and normal saline groups: p < 0.01). Proinflammatory factors were greatly decreased in lacrimal glands (p < 0.01). Leukocytes were identified and markedly decreased in conujnctiva (p < 0.01), inflammatory reaction of DED was greatly relieved. More importantly, the goblet cells were largely restored and ocular surface lesions were significantly ameliorated (p < 0.01). Thus, we observed FTY720 alleviated DED in NOD mice by inhibiting leukocytes, the function of ocular surface tissue in NOD mice was partially restored via inhibiting ocular surface inflammation and increasing the density of goblet cells and conjunctival epithelia. FTY720 may offer a novel strategy for the treatment of inflammatory disorders in the ocular surface." @default.
• W918310856 created "2016-06-24" @default.
• W918310856 creator A5009494612 @default.
• W918310856 creator A5030579237 @default.
• W918310856 creator A5077083488 @default.
• W918310856 creator A5083265775 @default.
• W918310856 creator A5090394453 @default.
• W918310856 creator A5090454827 @default.
• W918310856 date "2015-09-01" @default.
• W918310856 modified "2023-10-13" @default.
• W918310856 title "FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue" @default.
• W918310856 cites W1523354060 @default.
• W918310856 cites W1613206620 @default.
• W918310856 cites W1971369241 @default.
• W918310856 cites W1981980281 @default.
• W918310856 cites W1992063412 @default.
• W918310856 cites W1992656196 @default.
• W918310856 cites W1997816322 @default.
• W918310856 cites W2001968948 @default.
• W918310856 cites W2005178101 @default.
• W918310856 cites W2007262932 @default.
• W918310856 cites W2007294691 @default.
• W918310856 cites W2010539762 @default.
• W918310856 cites W2010954738 @default.
• W918310856 cites W2011438680 @default.
• W918310856 cites W2013555370 @default.
• W918310856 cites W2014207594 @default.
• W918310856 cites W2018180869 @default.
• W918310856 cites W2024921065 @default.
• W918310856 cites W2026731442 @default.
• W918310856 cites W2029515932 @default.
• W918310856 cites W2030379346 @default.
• W918310856 cites W2036170000 @default.
• W918310856 cites W2042919100 @default.
• W918310856 cites W2055947480 @default.
• W918310856 cites W2059921365 @default.
• W918310856 cites W2061640789 @default.
• W918310856 cites W2065687765 @default.
• W918310856 cites W2072021875 @default.
• W918310856 cites W2078226575 @default.
• W918310856 cites W2088675292 @default.
• W918310856 cites W2099738114 @default.
• W918310856 cites W2108813293 @default.
• W918310856 cites W2142263640 @default.
• W918310856 cites W2154089780 @default.
• W918310856 cites W2156726966 @default.
• W918310856 cites W2596391620 @default.
• W918310856 cites W2735954633 @default.
• W918310856 doi "https://doi.org/10.1016/j.exer.2015.06.032" @default.
• W918310856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26187517" @default.
• W918310856 hasPublicationYear "2015" @default.
• W918310856 type Work @default.
• W918310856 sameAs 918310856 @default.
• W918310856 citedByCount "13" @default.
• W918310856 countsByYear W9183108562016 @default.
• W918310856 countsByYear W9183108562017 @default.
• W918310856 countsByYear W9183108562021 @default.
• W918310856 countsByYear W9183108562022 @default.
• W918310856 crossrefType "journal-article" @default.
• W918310856 hasAuthorship W918310856A5009494612 @default.
• W918310856 hasAuthorship W918310856A5030579237 @default.
• W918310856 hasAuthorship W918310856A5077083488 @default.
• W918310856 hasAuthorship W918310856A5083265775 @default.
• W918310856 hasAuthorship W918310856A5090394453 @default.
• W918310856 hasAuthorship W918310856A5090454827 @default.
• W918310856 hasConcept C118487528 @default.
• W918310856 hasConcept C126322002 @default.
• W918310856 hasConcept C134018914 @default.
• W918310856 hasConcept C142724271 @default.
• W918310856 hasConcept C16685009 @default.
• W918310856 hasConcept C203014093 @default.
• W918310856 hasConcept C2775941134 @default.
• W918310856 hasConcept C2775984611 @default.
• W918310856 hasConcept C2776882836 @default.
• W918310856 hasConcept C2777397205 @default.
• W918310856 hasConcept C2778013207 @default.
• W918310856 hasConcept C2778275304 @default.
• W918310856 hasConcept C2779298748 @default.
• W918310856 hasConcept C529295009 @default.
• W918310856 hasConcept C555293320 @default.
• W918310856 hasConcept C55851684 @default.
• W918310856 hasConcept C71924100 @default.
• W918310856 hasConceptScore W918310856C118487528 @default.
• W918310856 hasConceptScore W918310856C126322002 @default.
• W918310856 hasConceptScore W918310856C134018914 @default.
• W918310856 hasConceptScore W918310856C142724271 @default.
• W918310856 hasConceptScore W918310856C16685009 @default.
• W918310856 hasConceptScore W918310856C203014093 @default.
• W918310856 hasConceptScore W918310856C2775941134 @default.
• W918310856 hasConceptScore W918310856C2775984611 @default.
• W918310856 hasConceptScore W918310856C2776882836 @default.
• W918310856 hasConceptScore W918310856C2777397205 @default.
• W918310856 hasConceptScore W918310856C2778013207 @default.
• W918310856 hasConceptScore W918310856C2778275304 @default.
• W918310856 hasConceptScore W918310856C2779298748 @default.
• W918310856 hasConceptScore W918310856C529295009 @default.
• W918310856 hasConceptScore W918310856C555293320 @default.
• W918310856 hasConceptScore W918310856C55851684 @default.

• next